Literature DB >> 11753652

Mutational analysis of the regulatory function of the c-Abl Src homology 3 domain.

B B Brasher1, S Roumiantsev, R A Van Etten.   

Abstract

The catalytic activity of the c-Abl tyrosine kinase is tightly regulated by its Src homology 3 (SH3) domain through a complex mechanism that may involve intramolecular binding to Pro242 in the linker region between the SH2 and catalytic domains as well as interactions with a trans-inhibitor. We analysed the effect of mutation or replacement of SH3 on c-Abl tyrosine kinase activity and transformation. Random mutagenesis of SH3 identified several novel point mutations that dysregulated c-Abl kinase activity in vivo, but the RT loop was insensitive to mutational activation. Activating SH3 mutations abolished binding of proline-rich SH3 ligands in vitro, while mutations at Ser140 in the connector between the SH3 and SH2 domains activated Abl kinase activity in vivo and in vitro but did not impair SH3 ligand-binding. Abl was regulated efficiently when its SH3 domain was replaced with a heterologous SH3 from c-Src that binds a different spectrum of proline-rich ligands, but not by substitution of a modular WW domain with similar ligand-binding specificity. These results suggest that the SH3 domain regulates Abl principally by binding to the atypical intramolecular ligand Pro242 rather than a canonical PxxP ligand. Coordination between the SH3 and SH2 domains mediated by the connector region may be required for regulation of Abl even in the absence of SH2 ligand binding.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11753652     DOI: 10.1038/sj.onc.1204978

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  12 in total

1.  Molecular dynamics and protein function.

Authors:  M Karplus; J Kuriyan
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-03       Impact factor: 11.205

2.  Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance.

Authors:  Mohammad Azam; Valentina Nardi; William C Shakespeare; Chester A Metcalf; Regine S Bohacek; Yihan Wang; Raji Sundaramoorthi; Piotr Sliz; Darren R Veach; William G Bornmann; Bayard Clarkson; David C Dalgarno; Tomi K Sawyer; George Q Daley
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-05       Impact factor: 11.205

3.  The Hippo pathway kinase Lats2 prevents DNA damage-induced apoptosis through inhibition of the tyrosine kinase c-Abl.

Authors:  N Reuven; J Adler; V Meltser; Y Shaul
Journal:  Cell Death Differ       Date:  2013-07-12       Impact factor: 15.828

4.  A unique set of SH3-SH3 interactions controls IB1 homodimerization.

Authors:  Ole Kristensen; Sylvie Guenat; Imran Dar; Nathalie Allaman-Pillet; Amar Abderrahmani; Mourad Ferdaoussi; Raphaël Roduit; Fabienne Maurer; Jacques S Beckmann; Jette S Kastrup; Michael Gajhede; Christophe Bonny
Journal:  EMBO J       Date:  2006-02-02       Impact factor: 11.598

5.  Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop.

Authors:  Sergei Roumiantsev; Neil P Shah; Mercedes E Gorre; John Nicoll; Bradley B Brasher; Charles L Sawyers; Richard A Van Etten
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-29       Impact factor: 11.205

6.  A direct binding site for Grb2 contributes to transformation and leukemogenesis by the Tel-Abl (ETV6-Abl) tyrosine kinase.

Authors:  Ryan P Million; Nari Harakawa; Sergei Roumiantsev; Lyuba Varticovski; Richard A Van Etten
Journal:  Mol Cell Biol       Date:  2004-06       Impact factor: 4.272

7.  Cdo binds Abl to promote p38alpha/beta mitogen-activated protein kinase activity and myogenic differentiation.

Authors:  Gyu-Un Bae; Bok-Geon Kim; Hye-Jin Lee; Ji-Eun Oh; Su-Jae Lee; Wei Zhang; Robert S Krauss; Jong-Sun Kang
Journal:  Mol Cell Biol       Date:  2009-05-26       Impact factor: 4.272

8.  Tyrosine phosphorylation in the SH3 domain disrupts negative regulatory interactions within the c-Abl kinase core.

Authors:  Shugui Chen; Linda P O'Reilly; Thomas E Smithgall; John R Engen
Journal:  J Mol Biol       Date:  2008-08-23       Impact factor: 5.469

9.  Mutation of Vav1 adaptor region reveals a new oncogenic activation.

Authors:  Lyra Razanadrakoto; Françoise Cormier; Vanessa Laurienté; Elisabetta Dondi; Laura Gardano; Shulamit Katzav; Lionel Guittat; Nadine Varin-Blank
Journal:  Oncotarget       Date:  2015-02-10

10.  Atomic view of the energy landscape in the allosteric regulation of Abl kinase.

Authors:  Tamjeed Saleh; Paolo Rossi; Charalampos G Kalodimos
Journal:  Nat Struct Mol Biol       Date:  2017-09-25       Impact factor: 15.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.